thalidomide has been researched along with Bone Diseases in 14 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Bone Diseases: Diseases of BONES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide is an effective maintenance therapy in patients with multiple myeloma." | 6.72 | Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. ( Attal, M; Avet-Loiseau, H; Benboubker, L; Berthou, C; Bourhis, JH; Caillot, D; Doyen, C; Dumontet, C; Facon, T; Garderet, L; Grobois, B; Harousseau, JL; Hulin, C; Leyvraz, S; Marit, G; Monconduit, M; Moreau, P; Pegourie, B; Renaud, M; Voillat, L; Yakoub Agha, I, 2006) |
| "Lenalidomide treatment resulted in significant increases in CT/FEM-derived estimates of bone strength." | 5.40 | A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography. ( Awai, K; Date, S; Kaichi, Y; Kiguchi, M; Kuroda, Y; Sakai, A; Sakoda, Y; Takasu, M; Tani, C, 2014) |
| "Treatment with lenalidomide, as the final therapeutic option, resolved the intractable melena and improved both the intestinal lesions and myeloma." | 5.39 | Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis. ( Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S, 2013) |
| "The Medical Research Council Myeloma IX Trial (ISRCTNG8454111) examined traditional and thalidomide-based induction and maintenance regimens and IV zoledronic acid (ZOL) and oral clodronate (CLO) in 1960 patients with newly diagnosed multiple myeloma." | 5.16 | Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. ( Ashcroft, AJ; Bell, SE; Child, JA; Davies, FE; Drayson, MT; Gregory, WM; Jackson, GH; Morgan, GJ; Owen, RG; Szubert, AJ, 2012) |
| "Thalidomide is an effective maintenance therapy in patients with multiple myeloma." | 2.72 | Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. ( Attal, M; Avet-Loiseau, H; Benboubker, L; Berthou, C; Bourhis, JH; Caillot, D; Doyen, C; Dumontet, C; Facon, T; Garderet, L; Grobois, B; Harousseau, JL; Hulin, C; Leyvraz, S; Marit, G; Monconduit, M; Moreau, P; Pegourie, B; Renaud, M; Voillat, L; Yakoub Agha, I, 2006) |
| " However, complications arising from their long-term use have prompted studies of schedule optimization and alternate strategies." | 2.47 | Advances in the biology and treatment of bone disease in multiple myeloma. ( Raje, N; Roodman, GD, 2011) |
| "Lenalidomide treatment resulted in significant increases in CT/FEM-derived estimates of bone strength." | 1.40 | A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography. ( Awai, K; Date, S; Kaichi, Y; Kiguchi, M; Kuroda, Y; Sakai, A; Sakoda, Y; Takasu, M; Tani, C, 2014) |
| "Treatment with lenalidomide, as the final therapeutic option, resolved the intractable melena and improved both the intestinal lesions and myeloma." | 1.39 | Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis. ( Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (35.71) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Roider, E | 1 |
| Signer, C | 1 |
| Fehrenbacher, B | 1 |
| Metzler, G | 1 |
| Schaller, M | 1 |
| Kamarachev, J | 1 |
| Kerl, K | 1 |
| Balabanov, S | 1 |
| Jochum, W | 1 |
| Hoetzenecker, W | 1 |
| Cozzio, A | 1 |
| French, LE | 1 |
| Dummer, R | 1 |
| Guenova, E | 1 |
| Nagano, S | 1 |
| Mori, M | 1 |
| Kato, A | 1 |
| Ono, Y | 1 |
| Aoki, K | 1 |
| Arima, H | 1 |
| Takiuchi, Y | 1 |
| Tabata, S | 1 |
| Yanagita, S | 1 |
| Matsushita, A | 1 |
| Ishikawa, T | 1 |
| Imai, H | 1 |
| Takahashi, T | 1 |
| Takasu, M | 1 |
| Tani, C | 1 |
| Kaichi, Y | 1 |
| Sakoda, Y | 1 |
| Kiguchi, M | 1 |
| Date, S | 1 |
| Kuroda, Y | 1 |
| Sakai, A | 1 |
| Awai, K | 1 |
| Laubach, J | 1 |
| Richardson, P | 1 |
| Anderson, K | 1 |
| Raje, N | 1 |
| Roodman, GD | 1 |
| Morgan, GJ | 2 |
| Davies, FE | 1 |
| Gregory, WM | 1 |
| Szubert, AJ | 1 |
| Bell, SE | 1 |
| Drayson, MT | 1 |
| Owen, RG | 1 |
| Ashcroft, AJ | 1 |
| Jackson, GH | 1 |
| Child, JA | 1 |
| Locke, FL | 1 |
| STAEMMLER, M | 1 |
| HELM, F | 1 |
| KIEL, H | 1 |
| DIPAOLO, JA | 1 |
| GATZEK, H | 1 |
| PICKREN, J | 1 |
| SULAMAA, M | 1 |
| RYOEPPY, S | 1 |
| DWORNIK, JJ | 1 |
| MOORE, KL | 1 |
| Joshua, DE | 1 |
| Attal, M | 1 |
| Harousseau, JL | 1 |
| Leyvraz, S | 1 |
| Doyen, C | 1 |
| Hulin, C | 1 |
| Benboubker, L | 1 |
| Yakoub Agha, I | 1 |
| Bourhis, JH | 1 |
| Garderet, L | 1 |
| Pegourie, B | 1 |
| Dumontet, C | 1 |
| Renaud, M | 1 |
| Voillat, L | 1 |
| Berthou, C | 1 |
| Marit, G | 1 |
| Monconduit, M | 1 |
| Caillot, D | 1 |
| Grobois, B | 1 |
| Avet-Loiseau, H | 1 |
| Moreau, P | 1 |
| Facon, T | 1 |
| Jörgensen, G | 1 |
3 reviews available for thalidomide and Bone Diseases
| Article | Year |
|---|---|
Multiple myeloma.
Topics: Anemia; Bone Diseases; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Proteinase Inhi | 2011 |
Advances in the biology and treatment of bone disease in multiple myeloma.
Topics: Biopsy; Bone Density Conservation Agents; Bone Diseases; Bone Marrow Cells; Bone Remodeling; Clinica | 2011 |
What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?
Topics: Bone Diseases; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Fractures, Bone; H | 2012 |
2 trials available for thalidomide and Bone Diseases
| Article | Year |
|---|---|
Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2012 |
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Diseases; Diphosphonates; Disease-Free Su | 2006 |
9 other studies available for thalidomide and Bone Diseases
| Article | Year |
|---|---|
Individualized treatment approaches for Langerhans cell histiocytosis.
Topics: Adrenal Cortex Hormones; Adult; Aged, 80 and over; Azetidines; Bone Diseases; Dermatologic Agents; F | 2018 |
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi | 2014 |
[CONGENITAL MALFORMATIONS OF SKELETON IN RABBITS].
Topics: Abnormalities, Drug-Induced; Animals; Bone Diseases; Female; Humans; Lagomorpha; Mucopolysaccharidos | 1964 |
MALFORMATIONS INDUCED IN THE MOUSE BY THALIDOMIDE.
Topics: Abnormalities, Drug-Induced; Animals; Bone Diseases; Embryo, Mammalian; Embryo, Nonmammalian; Female | 1964 |
CONGENITAL ABSENCE OF THE TIBIA.
Topics: Abnormalities, Drug-Induced; Amputation, Surgical; Bone Diseases; Bone Transplantation; Child; Conge | 1964 |
SKELETAL MALFORMATIONS IN THE HOLTZMAN RAT EMBRYO FOLLOWING THE ADMINISTRATION OF THALIDOMIDE.
Topics: Abnormalities, Drug-Induced; Animals; Bone Diseases; Female; Humans; Injections; Injections, Intrape | 1965 |
Multiple myeloma: the present and the future.
Topics: Antineoplastic Agents, Alkylating; Bone Diseases; Boronic Acids; Bortezomib; Diphosphonates; Humans; | 2005 |
[Genetic analysis of skeletal diseases. Genetic report].
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Bone and Bones; Bone Diseases; Child; Chromoso | 1973 |